Zurakowski and Jonas highlight a controversy as they ponder re-emergence of the Blalock shunt as initial therapy for tetralogy of Fallot (TOF). The authors first discuss early mortality and data analytics. These are intertwined. Rumors abound that some programs “game the system.” The authors point out that a tetralogy that receives a shunt and then months later a complete repair counts “twice” in the current system. However, some programs perform a shunt for a symptomatic neonatal TOF, not to game the system, but because they feel it gives the patient the best chance of survival at their institution. Not all programs have a dedicated cardiac intensive care unit full of double-boarded intensivists. Also, all patients are not able to travel to larger, regional centers.

Teaching neonatal surgery is difficult in today’s climate. The authors hit the mark with this discussion. It is incredibly challenging to take fellows through neonatal cases, and our specialty has morphed into one of completing the 1- or 2-year congenital heart surgery residency followed by (hopefully) employment with a colleague willing to mentor. An early primary TOF repair can be tricky, even for experienced surgeons.

The authors then discuss a Journal of the American College of Cardiology article comparing palliation followed by repair versus primary repair for TOF and point out myriad weaknesses. These include the following: lack of surgeon author on the manuscript; overstating mortality benefit based on not much difference between the 2 groups; and excluding those without 2-year follow-up reveals no difference in 2-year mortality rates. Also, they highlight the lack of definition for TOF in the article. However, the same investigators evaluated their own experience, with a surgeon author, and found similar survival but increased morbidity with neonatal complete repair. And, I disagree that one manuscript will lead to a surge in palliative shunting of asymptomatic infants.

Patients today seem smaller and more complex, but I disagree that 2 to 2.5 kg is “robust.” These patients often have poor tissue quality. Ductal stenting and infundibular stenting have changed the game for symptomatic TOF. The Congenital Catheterization Research Collaborative is investigating different methods of palliation. They compared ductal stenting with the Blalock in those with ductal dependent pulmonary blood flow and found no mortality difference. They plan to longitudinally examine all possible TOF interventions—initial palliation (Blalock, ductal stent, infundibular stent) followed by complete repair versus complete repair.

One area worth highlighting is that of neurologic/neurodevelopmental outcomes. There are many studies examining the brains and neurodevelopmental outcomes of patients with congenital heart disease. The data are mixed. Some examples include the following: volatile anesthetic agents having an association with worse neurodevelopmental outcomes; too much focus on the cardiopulmonary bypass circuit, as coarctation via left thoracotomy and arch repair with cardiopulmonary bypass via sternotomy have similar rates of neurodevelopmental delay;
postponing complete repair negatively impacts brain growth and language development; and patient factors may be more important than operative factors in predicting neurodevelopmental outcomes.

I congratulate the authors on a timely, thought-provoking article.

References

Commentary: Is there still a role for the systemic-to-pulmonary artery shunt in tetralogy?

Harold M. Burkhart, MD, a Jess L. Thompson, MD, a and Arshid Mir, MD b

The surgical treatment of tetralogy of Fallot (TOF) remains a great success story with the introduction of a palliative systemic-to-pulmonary artery shunt by Drs Blalock, Thomas, and Taussig followed with complete surgical repair by Lillehei and colleagues. Now, more than 70 years after initial surgical repair, there continues to be considerable debate over the optimal timing of repair of this lesion.

Although most tetralogy infants are amenable to primary repair, there exists at-risk neonates who benefit from staged palliation followed by complete repair.